Is RIGEL PHARMACEUTICALS INC (RIGL) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 11.4% / 30% | 14.8% / 30% | 7.9% / 30% | 1.17% / 5% | ✓ HALAL |
| DJIM | 11.4% / 33% | 14.8% / 33% | 7.9% / 33% | 1.17% / 5% | ✓ HALAL |
| MSCI | 36.6% / 33% | 47.2% / 33% | 25.4% / 33% | 1.17% / 5% | ✗ NOT HALAL |
| S&P | 11.4% / 33% | 14.8% / 33% | 7.9% / 33% | 1.17% / 5% | ✓ HALAL |
| FTSE | 36.6% / 33% | 47.2% / 33% | 25.4% / 50% | 1.17% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 82.0% | |
| Operating Margin | 33.2% | |
| Net Margin | 124.7% | |
| Return on Equity (ROE) | 185.9% | |
| Return on Assets (ROA) | 23.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $76M |
| Free Cash Flow | $76M |
| Total Debt | $53M |
| Debt-to-Equity | 13.6 |
| Current Ratio | 2.4 |
| Total Assets | $514M |
Price & Trading
| Last Close | $26.37 |
| 50-Day MA | $32.43 |
| 200-Day MA | $32.89 |
| Avg Volume | 420K |
| Beta | 1.2 |
|
52-Week Range
$15.50
| |
About RIGEL PHARMACEUTICALS INC (RIGL)
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Purification Calculator
As a halal stock with 1.17% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is RIGEL PHARMACEUTICALS INC (RIGL) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), RIGEL PHARMACEUTICALS INC is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is RIGEL PHARMACEUTICALS INC's debt ratio?
RIGEL PHARMACEUTICALS INC's debt ratio is 11.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 36.6%.
Does RIGEL PHARMACEUTICALS INC require dividend purification?
Yes, RIGEL PHARMACEUTICALS INC has an impermissible income ratio of 1.17%, which means 1.17% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are RIGEL PHARMACEUTICALS INC's key financial metrics?
RIGEL PHARMACEUTICALS INC has a market capitalization of $477M, trailing P/E ratio of 1.3, and revenue of $294M. The company maintains a gross margin of 82.0% and a net margin of 124.7%. Return on equity stands at 185.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.